COST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEY

Basit Öğe Kaydı
dc.authorwosidTörüner, Murat/AAQ-1826-2020
dc.contributor.authorArhan, M.
dc.contributor.authorTezel, H. A.
dc.contributor.authorToruner, M.
dc.contributor.authorBilaloglu, B.
dc.contributor.authorKoral, S.
dc.contributor.authorOzer, E.
dc.date.accessioned2024-06-12T11:20:31Z
dc.date.available2024-06-12T11:20:31Z
dc.date.issued2018
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1016/j.jval.2018.09.863
dc.identifier.endpageS145en_US
dc.identifier.issn1098-3015
dc.identifier.issn1524-4733
dc.identifier.startpageS145en_US
dc.identifier.urihttps://doi.org/10.1016/j.jval.2018.09.863
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25649
dc.identifier.volume21en_US
dc.identifier.wosWOS:000459985601184en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofValue In Healthen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleCOST-EFFECTIVENESS ANALYSIS OF USTEKINUMAB VERSUS ADALIMUMAB, INFLIXIMAB AND VEDOLIZUMAB FOR THE TREATMENT OF PATIENTS WITH MODERATELY TO SEVERE ACTIVE CROHN'S DISEASE FOR TURKEYen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu